A Multicentre Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment
Latest Information Update: 18 May 2026
At a glance
- Drugs Regorafenib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms REGOMAIN
Most Recent Events
- 20 Jan 2021 Planned End Date changed to 7 Jan 2025.
- 18 Dec 2020 New trial record